O33 SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 mg AND 50 mg DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS

Autor:	P. S. Mantry, Michael N. Robertson, Alnoor Ramji, N. Mobashery, Martin Lagging, Peggy Hwang, J. Talaty, O.R. Weiland, Frank Weilert, I.N. Gendrano, B. Zhang, Janice Wahl, Ashley Brown, John M. Vierling
Rok vydání:	2014
Předmět:	Therapy naive medicine.medical_specialty Hepatology business.industry Internal medicine Genotype medicine business Gastroenterology
Zdroj:	Journal of Hepatology. 60:S14
ISSN:	0168-8278
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::de1807b0f1d015c1ac198d33f3f4d87f https://doi.org/10.1016/s0168-8278(14)60035-0 Zobrazit plný text záznamu Full Text from ScienceDirect